Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers

European Journal of Ophthalmology

Volumn 18, Issue 1, 2008, Pages 13-20

  Chiambaretta, Frédéric ^a,b   Garraffo, R ^a   Elena, P P ^a   Pouliquen, P ^a   Delval, L ^a   Rigal, D ^a   Dubray, C ^a   Goldschmidt, P ^a   Tabbara, K ^a   Cochereau, I ^a  

^a CRNH AUVERGNE   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Area under the inhibitory curve (AUIC); Azithromycin eyedrops; Minimal inhibitory concentration (MIC); T1225; Tear pharmacokinetics pharmacodynamics

Indexed keywords

AZITHROMYCIN; EYE DROPS; T 1225; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG RELEASE; DRUG TOLERABILITY; EYELID EDEMA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LACRIMAL FLUID; MALE; MASS SPECTROMETRY; NORMAL HUMAN; NOSE IRRITATION; PAPILLARY CONJUNCTIVITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOLUNTEER;

EID: 41149096153     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800103     Document Type: Article

References (48)

1. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999; 74: 613-34.
2. Blondeau JM, DeCarolis E, Metzler KL, Hansen GT. The macrolides. Expert Opin Investig Drugs 2002; 11:189-215.
3. Drew RH, Gallis HA. Azithromycin-spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy 1992; 12: 161-73.
4. Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004; 10: 3045-53.
5. Mattoes HM, Nightingale CH. Pharmacokinetics/pharmacodynamics of macrolides. In: Schönfeld W, Kirst HA, eds. Macrolide Antibiotics. Basel, Switzerland: Birkhaüser Verlag, 2002; 25-36.
6. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997; 16: 438-43.
7. Retsema J, Fu W. Macrolides: structures and microbial targets. Int J Antimicrob Agents 2001; 18 (Suppl): S3-10.
8. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 2004; 18: 621-49.
9. Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother 1999; 11: 107-18.
10. World Health Organization, Programme for the Prevention of Blindness and Deafness. Future approaches to trachoma control. Report of a global scientific meeting. Geneva, Switzerland; 17-20 June 1996. WHO/PBL/96.56: 1997; 1-44.
11. Karcioglu ZA, El Yazigi A, Jabak MH, Choudhury AH, Ahmed WS. Pharmacokinetics of azithromycin in trachoma patients: serum and tear levels. Ophthalmology 1998; 105: 658-61.
12. Tabbara KF, al Kharashi SA, al Mansouri SM, et al. Ocular levels of azithromycin. Arch Ophthalmol 1998; 116:1625-8.
13. World Health Organization. Report of the First Meeting of the WHO Alliance for the Global Elimination of Trachoma. Geneva, Switzerland; 30 June-1 July 1997. WHO/PBL/GET/97.1: 1997; 1-33.
14. Wikler MA, Cockerill FR, Craig WA, et al. Performance standards for antimicrobial susceptibility testing; Sixteenth informational supplement. CLSI document M100-S16. Clinical and Laboratory Standards Institute. Wayne, USA 2006; 26:1-185.
15. Soussy CJ. Comité de l'antibiogramme de la Société Française de Microbiologie. Communiqué 2006. (Edition Janvier 2006. Mise à jour en Novembre 2006.) Société Française de Microbiologie (SFM) 2006; 1 -45.
16. Jaruratanasirikul S, Hortiwakul R, Tantisarasart T, Phuenpathom N, Tussanasunthornwong S. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother 1996; 40: 825-6.
17. Gordon EM, Blumer JL. Rationale for single and high dose treatment regimens with azithromycin. Pediatr Infect Dis J 2004; 23: S102-7.
18. Scieux C, Bianchi A, Chappey B, Vassias I, Perol Y. In-vitro activity of azithromycin against Chlamydia trachomatis. J Antimicrob Chemother 1990; 25 (Suppl): S7-10.
19. Slaney L, Chubb H, Ronald A, Brunham R. In-vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis. J Antimicrob Chemother 1990; 25 Suppl A: 1-5.
20. Fechner PU, Teichmann KD. The conjunctiva. In: Fechner PU, Teichmann KD, eds. Ocular therapeutics pharmacology and clinical application. Thorofare, NJ: Slack Inc., 1998; 15: 285-326.
21. Barry AL, Jones RN, Thornsberry C. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother 1988; 32: 752-4.
22. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44: 750-99.
23. Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician 1998; 57: 735-46.
24. Soukiasian SH, Baum J. Bacterial conjunctivitis. 2nd edition. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. Philadelphia: Elsevier Mosby, 2005; 49: 615-28.
25. Syed NA, Chandler JW. Bacterial conjunctivitis. In: Tabbara KF, Hyndiuk RA, eds. Infections of the eye. Boston: Little, Brown and Co., 1996; 27: 423-31.
26. Ben Ali F, Golstein FW, Acar JF. In vitro activity of macrolides against traditional susceptible bacteria. In: Schönfeld W, Kirst HA, eds. Macrolide Antibiotics. Basel, Switzerland: Birkhaüser Verlag, 2002; 185-200.
27. Gigliotti F, Williams WT, Hayden FG, et al. Etiology of acute conjunctivitis in children. J Pediatr 1981; 98: 531-6.
28. Gross RD, Hoffman RO, Lindsay RN. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin Pediatr (Phila) 1997; 36: 435-44.
29. AFSSAPS. Spectres d'activité antimicrobienne. Répertoire de spectres validés par la commission d'autorisation de mise sur le marché 2005; 1-251.
30. Baum J. Antibiotic mechanisms. 2nd edition. In: Smolin G, Thoft RA, eds. The Cornea: Scientific Foundations and Clinical Practice. 2nd edition. Boston: Little, Brown and Co., 1987; 4: 179-89.
31. Hunt GS, Citron DM, Claras MC, Goldstein EJ. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Antimicrob Agents Chemother 1996; 40: 2413-5.
32. Philippon A, Cluzel R, Soussy CJ. Azithromycine: points critiques. Pathol Biol (Paris) 1995; 43: 488-97.
33. Borrmann L, Tang-Liu DD, Kann J, Nista J, Lin ET, Frank J. Ofloxacin in human serum, urine, and tear film after topical application. Cornea 1992; 11: 226-30.
34. Friedlaender MH, Rubin JM, Padilla E, Amdahl LD. Levofloxacin concentration in tears following topical administration of 0.5% levofloxacin ophthalmic solution. Invest Ophthalmol Vis Sci 2000; 41: 763.
35. Hanna C, Massey JY, Hendrickson RO, Williamson J, Jones EM, Wilson P. Ocular penetration of topical chloramphenicol in humans. Arch Ophthalmol 1978; 96: 1258-61.
36. Limberg M, Bugge C. Tear concentrations of topically applied ciprofloxacin. Cornea 1994; 13: 496-9.
37. Raizman MB, Rubin JM, Graves AL, Rinehart M. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. Clin Ther 2002; 24: 1439-50.
38. Scuderi AC, De Lazzari A, Miano F, Zola P. Residence time of netilmicin in tears. Cornea 2002; 21: 48-50.
39. Walters TR, Hart W. Tear concentration of 1.5% levofloxacin ophthalmic solution following topical administration in healthy adult volunteers. Invest Ophthalmol Vis Sci 2003; 44: 4453/B112.
40. Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001; 18 (Suppl): S17-23.
41. Wang MG, Zhang YY, Zhu DM, Zhang J, Shi YG. Postantibiotic effects of eleven antimicrobials on five bacteria. Acta Pharmacol Sin 2001; 22: 804-8.
42. Danesi R, Lupetti A, Barbara C, et al. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother 2003; 51: 939-45.
43. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 2001; 29 (Suppl): S11-5.
44. Peric M, Browne FA, Jacobs MR, Appelbaum PC. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic break-points in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Clin Ther 2003; 25: 169-77.
45. Zhanel GG, DeCorby M, Noreddin A, et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 2003; 52: 83-8.
46. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33 (Suppl): S233-7.
47. Cochereau I, Goldschmidt P, Goepogui A, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children - a randomised, controlled, double-masked clinical trial. Br J Ophthalmol 2006; 91: 667-72.
48. Cochereau I, Meddeb-Ouertani A, Khairallah M, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol 2007; 91: 465-9.